Clin2
NCT06978114Possibly a fitRecruiting

Study of a new drug for advanced bile duct cancer

Advanced Biliary Tract Cancer

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests a new drug called BL-B01D1 combined with an immunotherapy for people with advanced bile duct cancer. It aims to see if this combination can help shrink tumors or slow the disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
46 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have advanced bile duct cancer confirmed by a biopsy or cytology.
  • You must be between 18 and 75 years old.
  • Your overall health must be good enough to be up and about (ECOG score 0 or 1).
  • You must have a tumor sample available from within the last 3 years for testing.
  • You must not have had certain other treatments within the last 4 weeks.
  • You must not have active infections like hepatitis B or C, HIV, or tuberculosis.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06405425Recruiting· Phase 2
Study of BL-B01D1 and immunotherapy for advanced bladder cancer

This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.

Shanghai, Shanghai Municipality
NCT06471205Recruiting· Phase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer

This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.

Shanghai, Shanghai Municipality
NCT07729956Not yet recruiting· Phase 3
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer

This trial tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) against a standard chemo/immu-notherapy combination. It is for people with previously untreated, advanced triple-negative breast cancer whose tumors have a protein called PD-L1.

Shanghai, Shanghai Municipality
NCT07054567Recruiting· Phase 2
Study of BL-B01D1 plus Keytruda for advanced cervical or endometrial cancer

This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.

Shanghai, Shanghai Municipality
NCT07733115Recruiting· Phase 2
Drug combo for advanced bile duct cancer

This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.

Shanghai
NCT06986785Recruiting· Phase 2
Study of new drug combinations for advanced liver cancer

This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.

Shanghai, Shanghai Municipality

Hear when a new Advanced Biliary Tract Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.